Myocardial InfarctionNCT04460482
Near-infrared Spectroscopy Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
A study testing Near-infrared spectroscopy (NIRS) and Angiography in people with Myocardial Infarction and Coronary Artery Disease, run by Odense University Hospital at 1 site in Denmark.
Trial summary
The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia
- What is being tested?
- Near-infrared spectroscopy (NIRS) and Angiography
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2020to 2 Mar 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with acute coronary syndrome (ST-elevation myocardial infarction and non-ST elevation myocardial infarction) referred for invasive coronary angiography and percutaneous coronary intervention at Department of Cardiology, Odense University Hospital (Odense, Denmark)
Who cannot join
- participation in other randomized clinical trials
- life expectancy < 1 year
- allergy to aspirin, clopidogrel, ticagrelor or prasugrel
- eGFR < 30 mL/min
- tortuous and angiographically estimated extremely calcified lesions
- ostial, left main and bifurcation lesions
Show all 9Show fewer
- lesions in a reference vessel diameter < 2.0 mm
- hemodynamic instability
- Scheduled for coronary artery bypass grafting
Trial locations and contacts
1 site in 1 country.
About this study
The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention.
Read the detailed description
Background Myocardial infarction (MI) secondary to atherosclerotic coronary artery disease is mainly due to plaque-rupture with formation of a luminal thrombogenic material. Lesions responsible for MI are more frequently composed of lipid-rich plaques (LRP) in both culprit and in non-culprit lesions compared to lesions in patients with stable angina.
LRP is thought to be main precursor for future coronary events and may also have an impact on complications following percutaneous coronary intervention (PCI). It has been previously indicated that stent thrombosis (ST) and restenosis often occur when stenting a lipid-rich plaque. And if using angiography guidance only during PCI, there is a potential risk of implantation of a stent edge on a lipid pool, which can result in incomplete stent coverage of a lesion. The incidence of restenosis and ST may be related to the lesion characteristics, clinical presentation, antithrombotic treatment and stent design. Other factors may include inflammatory reaction to the polymer coating containing drug that delays vascular healing, insufficient stent strut coverage and incomplete stent apposition (ISA).
Invasive imaging modality can contribute to better understanding of the changes that occur in the vessel wall during stent implantation.
Intravascular ultrasound (IVUS) combined with a new imaging modality called near-infrared spectroscopy (NIRS) can identify LRP and provide a semi-quantitative estimate of amount of LRP present within selected region of interest. The method is excellent to identify ISA and improve stent implantation technique.
Optical coherence tomography (OCT) is a high resolution imaging modality that can analyze healing pattern after stent implantation such as stent strut coverage.
Method The study is designed as a prospective randomized trial conducted at a single center (Odense University Hospital). Patients with MI will be enrolled if they fulfill the criteria. The study is submitted and approved by The Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20200010) and Danish Data Agency (Journal nr.: 20/18008).
Eligible patients will be randomly assigned to either NIRS-guided PCI or conventual angiography-guided PCI with implantation of Everolimus-eluting Xience stent, which is CE marked. NIRS will be performed in both groups after predilation and stent implantation. In NIRS-guided group the analyses will be used to identify LRP, and to measure vessel wall diameter in reference segments and lesion length. In angiography-guided group the analyses will not be available for the PCI operator and are for observation purpose only. OCT will be performed in both groups after stent implantation, but will be only available for interpretation in NIRS-guided group. In case of reintervention in NIRS-guided group, a final OCT will be performed.
Optimal PCI criteria were following: 1) minimum stent area (MSA) ≥ 5.5 mm2 and ≥ 90% of the distal reference lumen area; 2) no major stent malapposition; 3) plaque burden < 50% at stent edge border; 4) LCBI4mm < 150 in reference segments; and 5) no major stent edge dissection. In case of 1-3, we recommended additional post-dilatation, and in case of 4-5 we recommended an additional stent.
A significant LRP was with lipid-core burden index (maxLCBI4mm) ≥ 150.
Patients will be contacted by telephone to evaluate the clinical situation and to reduce the potential risk of dropout. After 6 months OCT will be performed in both groups to evaluate stent strut coverage and vessel healing.
Statistics Assuming data are normally distributed, categorical data will be presented as numbers and frequencies and compared using chi2-test. Continuous data will be presented as mean ± SD and compared using Student t test. SPSS version 26.0 will be used for the statistical analysis.
Sample size calculation Based on a previous study IVUS-guided PCI in STEMI, the percentage of covered stent struts was 85.4%±7.9. We hypothesized that the coverage in angiography-guided group will be lower by 5.6% at 6 month. A sample size of 86 patients (43 patients in each group) was required for the study to have a power of 80% and two-tailed significance level of 0.05. We expected a dropout rate of 20%, and 104 patients were required to be recruited in the trial.
Sato N, Minami Y, Shimohama T, Kameda R, Tojo T, Ako J. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Health Sci Rep. 2019;2(1):e105.
- Conditions
- Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia, Atherosclerosis, Lipid-Rich Atherosclerosis of Coronary Artery, Vascular Diseases
- Being tested
- Near-infrared spectroscopy (NIRS), Angiography
- Keywords
- drug-eluting stent, near-infrared spectrocopy, intravascular ultrasound, optical coherence tomography
- Medical subject headings
- Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia, Atherosclerosis, Vascular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Near-infrared spectroscopy (NIRS)Device
NIRS-guided PCI
AngiographyDevice
Angiography guided PCI
| Study group | Role | What they receive |
|---|---|---|
| NIRS-guided PCI | Active comparator | Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent Receives: Device: Near-infrared spectroscopy (NIRS) |
| Angiography-guided PCI | Active comparator | Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent Receives: Device: Angiography |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of stent strut coverage
Proportion of stent strut coverage at 6 months follow up estimated by OCT
Measured: 6 months after index percutaneous coronary intervention
Secondary outcomes (3)
Uncovered stent struts
Measured: 6 months after index percutaneous coronary intervention
Persistent stent malapposition
Measured: 6 months after index percutaneous coronary intervention
Maximal neointimal growth
Measured: 6 months after index percutaneous coronary intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2020
- Study start1 Sep 2020
- Primary completion1 Sep 2022
- Study completion2 Mar 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by Odense University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Eligible patients randomized to NIRS-guided or standard angiographic-guided intervention with DES
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 104 participants (actual)
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Manijeh Noori, Odense University Hospital
- Investigators
- Lisette Okkels Jensen, MD PhD Prof, Study chair, Odense University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04460482
- Sponsor's protocol ID
- s-20200010
- Status last verified
- Jun 2025
- First submitted
- 2 Jul 2020
- Last updated
- 11 Jun 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Noori M, Hougaard M, Maehara A, Troan J, Hansen KN, Junker A, Hansen HS, Veien K, Ellert J, Lassen JF, Jensen LO. Multimodality Intravascular Imaging Guidance (NIRS-IVUS-OCT) Compared to Angiography-Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: The NIRVUS Trial. Catheter Cardiovasc Interv. 2026 Jul 28. doi: 10.1002/ccd.70765. Online ahead of print.
PubMed 42521403
Study at a glance
From the registry record, last updated by the sponsor on 11 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Near-infrared Spectroscopy Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
- ClinicalTrials.gov ID
- NCT04460482
- Acronym / sponsor ID
- s-20200010
- Conditions
- Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia, Atherosclerosis, Lipid-Rich Atherosclerosis of Coronary Artery, Vascular Diseases
- Keywords
- drug-eluting stent, near-infrared spectrocopy, intravascular ultrasound, optical coherence tomography
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 104 participants (actual)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Study start
- 1 Sep 2020 (actual)
- Primary completion
- 1 Sep 2022 (actual)
- Study completion
- 2 Mar 2023 (actual)
- First posted
- 7 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention.
Detailed description
Background Myocardial infarction (MI) secondary to atherosclerotic coronary artery disease is mainly due to plaque-rupture with formation of a luminal thrombogenic material. Lesions responsible for MI are more frequently composed of lipid-rich plaques (LRP) in both culprit and in non-culprit lesions compared to lesions in patients with stable angina.
LRP is thought to be main precursor for future coronary events and may also have an impact on complications following percutaneous coronary intervention (PCI). It has been previously indicated that stent thrombosis (ST) and restenosis often occur when stenting a lipid-rich plaque. And if using angiography guidance only during PCI, there is a potential risk of implantation of a stent edge on a lipid pool, which can result in incomplete stent coverage of a lesion. The incidence of restenosis and ST may be related to the lesion characteristics, clinical presentation, antithrombotic treatment and stent design. Other factors may include inflammatory reaction to the polymer coating containing drug that delays vascular healing, insufficient stent strut coverage and incomplete stent apposition (ISA).
Invasive imaging modality can contribute to better understanding of the changes that occur in the vessel wall during stent implantation.
Intravascular ultrasound (IVUS) combined with a new imaging modality called near-infrared spectroscopy (NIRS) can identify LRP and provide a semi-quantitative estimate of amount of LRP present within selected region of interest. The method is excellent to identify ISA and improve stent implantation technique.
Optical coherence tomography (OCT) is a high resolution imaging modality that can analyze healing pattern after stent implantation such as stent strut coverage.
Method The study is designed as a prospective randomized trial conducted at a single center (Odense University Hospital). Patients with MI will be enrolled if they fulfill the criteria. The study is submitted and approved by The Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20200010) and Danish Data Agency (Journal nr.: 20/18008).
Eligible patients will be randomly assigned to either NIRS-guided PCI or conventual angiography-guided PCI with implantation of Everolimus-eluting Xience stent, which is CE marked. NIRS will be performed in both groups after predilation and stent implantation. In NIRS-guided group the analyses will be used to identify LRP, and to measure vessel wall diameter in reference segments and lesion length. In angiography-guided group the analyses will not be available for the PCI operator and are for observation purpose only. OCT will be performed in both groups after stent implantation, but will be only available for interpretation in NIRS-guided group. In case of reintervention in NIRS-guided group, a final OCT will be performed.
Optimal PCI criteria were following: 1) minimum stent area (MSA) ≥ 5.5 mm2 and ≥ 90% of the distal reference lumen area; 2) no major stent malapposition; 3) plaque burden < 50% at stent edge border; 4) LCBI4mm < 150 in reference segments; and 5) no major stent edge dissection. In case of 1-3, we recommended additional post-dilatation, and in case of 4-5 we recommended an additional stent.
A significant LRP was with lipid-core burden index (maxLCBI4mm) ≥ 150.
Patients will be contacted by telephone to evaluate the clinical situation and to reduce the potential risk of dropout. After 6 months OCT will be performed in both groups to evaluate stent strut coverage and vessel healing.
Statistics Assuming data are normally distributed, categorical data will be presented as numbers and frequencies and compared using chi2-test. Continuous data will be presented as mean ± SD and compared using Student t test. SPSS version 26.0 will be used for the statistical analysis.
Sample size calculation Based on a previous study IVUS-guided PCI in STEMI, the percentage of covered stent struts was 85.4%±7.9. We hypothesized that the coverage in angiography-guided group will be lower by 5.6% at 6 month. A sample size of 86 patients (43 patients in each group) was required for the study to have a power of 80% and two-tailed significance level of 0.05. We expected a dropout rate of 20%, and 104 patients were required to be recruited in the trial.
Sato N, Minami Y, Shimohama T, Kameda R, Tojo T, Ako J. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Health Sci Rep. 2019;2(1):e105.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Eligible patients randomized to NIRS-guided or standard angiographic-guided intervention with DES
| Arm | Type | Receives |
|---|---|---|
| NIRS-guided PCI | Active comparator | Device: Near-infrared spectroscopy (NIRS)Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent |
| Angiography-guided PCI | Active comparator | Device: AngiographyAngiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with acute coronary syndrome (ST-elevation myocardial infarction and non-ST elevation myocardial infarction) referred for invasive coronary angiography and percutaneous coronary intervention at Department of Cardiology, Odense University Hospital (Odense, Denmark)
Key exclusion criteria (9 listed)
- participation in other randomized clinical trials
- life expectancy < 1 year
- allergy to aspirin, clopidogrel, ticagrelor or prasugrel
- eGFR < 30 mL/min
- tortuous and angiographically estimated extremely calcified lesions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Near-infrared spectroscopy (NIRS)NIRS-guided PCI | Device | NIRS-guided PCI |
| AngiographyAngiography guided PCI | Device | Angiography-guided PCI |
Primary outcome
Proportion of stent strut coverage
Time frame: 6 months after index percutaneous coronary intervention
Proportion of stent strut coverage at 6 months follow up estimated by OCT
3 secondary outcomes
Uncovered stent struts
Time frame: 6 months after index percutaneous coronary intervention
Persistent stent malapposition
Time frame: 6 months after index percutaneous coronary intervention
Maximal neointimal growth
Time frame: 6 months after index percutaneous coronary intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jun 2025.
- Derived from this study: PubMed 42521403Noori M, Hougaard M, Maehara A, Troan J, Hansen KN, Junker A, Hansen HS, Veien K, Ellert J, Lassen JF, Jensen LO. Multimodality Intravascular Imaging Guidance (NIRS-IVUS-OCT) Compared to Angiography-Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction: The NIRVUS Trial. Catheter Cardiovasc Interv. 2026 Jul 28. doi: 10.1002/ccd.70765. Online ahead of print.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
Active, not recruitingObservational study
A Longitudinal Cohort Study to Evaluate Cardiovascular Risk Factors and Disease in Haiti
Hypertension, Diabetes
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lisette Okkels Jensen, MD PhD Prof study chair
Odense University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Near-infrared spectroscopy (NIRS) and Angiography in people with Myocardial Infarction and Coronary Artery Disease, run by Odense University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of stent strut coverage (time frame: 6 months after index percutaneous coronary intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04460482, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jun 2025.